

Subject, city, state	Effective date
MOBLEY CHIROPRACTIC FAMILY, ZACHARY, LA	12/11/96
SOUTHWEST MEDICAL INC., LITTER ROCK, AR	12/11/96
STACO MARKETING & SUPPLY INC., LITTER ROCK, AR	12/11/96

DEFAULT ON HEAL LOAN

AMAYA, ABRAHAM, LOS ALAMITOS, CA	12/09/96
AMUDOAGHAN, WALNETTE C., COUNTRY CLUB HILLS, IL	12/11/96
BRANVOLD, RONALD D., SUSANVILLE, CA	12/09/96
BUTTERFIELD, CATHY L. RICHARDS, BOISE, ID	12/09/96
CATRON, MARK W., CARTHAGE, MO	12/11/96
COLLIER, GEORGE R. JR., PONDERAY, ID	12/09/96
COMER, MICHAEL J., ELK GROVE, CA	12/09/96
CORTEZ, LINDA GUILLEN, CARMICHAEL, CA	12/09/96
DAVIS, PATRICIA M., STAMFORD, CT	12/11/96
EIMERS, JERRY L., MARYVILLE, MO	12/11/96
FICKEL, THEODORE E., SANTA BARBARA, CA	12/09/96
FOROUTANZAD, JOHN, LOS ANGELES, CA	12/09/96
FOX, RICHARD T., ARLINGTON, WA	12/09/96
HAMILTON, AARON J., RANCHO SANTA MARGARITA, CA	12/09/96
HEER, JOEL M., DUBUQUE, IA	12/11/96
KUTLER, MURRAY A., OMAHA, NE	12/11/96
LENTELL, BRIAN M., CLOVIS, CA	12/09/96
LIEN, DOUGLAS A., HOMER, AK	12/09/96
MACKEY, CYNTHIA K., MARINA DEL REY, CA	12/09/96
MCLAUGHLIN, ROBERT M., SUMMERSET, CA	12/09/96
MULLINS, MARILYN E., PLACENTIA, CA	12/12/96
NICHOLS, MARCUS F., CULVER CITY, CA	12/12/96
QUADLANDER, MICHAEL E., NEW BRAUNFELS, TX	12/11/96
ROYAL, DON C., NEWPORT BEACH, CA	12/12/96
SANDERS, THOMAS, KANSAS CITY, MO	12/11/96
SCHLATER, THEODORE L. III, LOS ANGELES, CA	12/09/96
SCHOW, KENNETH M., UNTINGTON BEACH, CA	12/09/96
SCINTA, MARK C., PHOENIX, AZ	12/09/96
SCOTT, BARBARA J., MILANES, NORTHRIDGE, CA	12/09/96
SHAW, MICHAEL G., INGLEWOOD, CA	12/09/96
SHOOLEH, HOSSIEN M., COSTA MESA, CA	12/09/96
SIMON, GREG L., MURRIETA, CA	12/09/96
SMITH, CURTIS L., SPENCER, OK	12/11/96
SMULKER, EVIE L., LOS ANGELES, CA	12/09/96
SPARROW, CLEVELAND B. JR., PONTIAC, MI	12/11/96
STEWART, JEANNINE L., NEWPORT BEACH, CA	12/09/96
SUTTON, BRIAN L., MISSION VIEJO, CA	12/09/96
TALLEY, MICHAEL S., BELTON, MO	12/11/96
TAYLOR, DAVID G., BLUE SPRINGS, MO	12/11/96
VAN PATTEN, MERRILL D., MASA, AZ	12/09/96
VARDANIAN, MICHAEL A., BULLERTON, CA	12/09/96
VESSELS, STEVEN L., LOMA LINDA, CA	12/09/96
VORBECK, THERESA M., ST LOUIS, MO	12/11/96
WALLS-FENWICK, JAN D., SAN BERNARDINO, CA	12/09/96
WEBBER, BARRY R., BURBANK, CA	12/09/96
WILLIAMS, PAMELA A., BUENA PARK, CA	12/09/96
WILLIAMS, DAVID L., PASADENA, CA	12/09/96
WOIWOOD, DAVID V., W. DES MOINES, IA	12/11/96
WOLTER, CARL F., LOS ANGELES, CA	12/09/96
YOUNG, KERRY V., IDAHO FALLS, ID	12/09/96

Dated: December 6, 1996.

William M. Libercci,

Director, Health Care Administrative Sanctions, Office of Enforcement and Compliance.

[FR Doc. 96-31986 Filed 12-16-96; 8:45 am]

BILLING CODE 4154-04-P

National Institutes of Health**Submission for OMB Review;
Comment Request; Women's Health
and Aging Study—Telephone Follow-
up**

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has submitted to the Office of Management and Budget

(OMB) a request to review and approve the information collection listed below. A notice regarding this proposed information collection was previously published in the Federal Register on August 20, 1996, page 43064. The notice allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The NIH may not conduct or sponsor, and the respondent is not required to respond to, an information collection

that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: *Title:* Women's Health and Aging Study—Telephone Follow-up. *Type of Information Collection Request:* Revision. *Need and Use of Information Collection:* This proposed study is designed to obtain additional data on women (previously examined in the Women's Health and Aging Study, OMB No. 0925-0376, expiration 8/31/97) through telephone interviews with participants or their proxies 1 and 2 years after their final in-home contacts. The Women's Health and Aging Study (WHAS) is a community-based prospective epidemiologic study whose goal is to study the causes and course of physical disability in the one-third most disabled women living in the community. The main objective of this additional data collection is to obtain information on disability and nursing home admission that will serve as end points in 5-year prospective analyses. This information will be a valuable addition to outcome data on death and hospital admissions that will be obtained through linkage with the National Death Index and the Health Care Financing Administration Medicare data base for this same period of time. The variables collected in the follow-up telephone assessments will provide important endpoints for a great many analyses that address the primary goal of the study, evaluating factors related to the progression of disability and need for long-term care. *Frequency of Response:* Once a year. *Affected Public:* Individuals or households. *Type of Respondents:* Women age 68 and older. *Estimated Number of Respondents:* 690; *Estimated Number of Responses per Respondent:* 2; *Average Burden Hours Per Response:* .33; *Estimated Total Annual Burden Hours Requested:* 326. The annualized cost to respondents is estimated at: \$7,500. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility,

and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

DIRECT COMMENTS TO OMB: Written comments and/or suggestions regarding the item(s) contained in this notice especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Jack Guralnik, Chief Epidemiology and Demography Office, Epidemiology, Demography, and Biometry Program, NIA, NIH, Gateway Building, Room 3C309, 7201 Wisconsin Avenue MSC 9205, Bethesda, MD 20892-9205, or call non-toll-free number (301) 496-1178 or E-mail your request, including your address to: <G48S@nih.gov>.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before January 16, 1997.

Colleen Barros,

Executive Office, NIA.

[FR Doc. 96-31882 Filed 12-16-96; 8:45 am]

BILLING CODE 4140-01-M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A signed

Confidential Disclosure Agreement will be required to receive copies of the patent applications.

4'- and 4'',4''-Substituted-3 α (diphenylmethoxy)tropane Analogs As Cocaine Therapeutics

AH Newman, AC Allen, RH Kline, S. Izenwasser, JL Katz (NIDA)
Serial No. 08/667,024 filed 20 Jun 96
(claiming benefit of 60/000,378 filed 21 Jun 95)

Licensing Contact: Leopold J. Luberecki, Jr., 301/496-7735 ext. 223

The invention provides a series of 4'- and 4'',4''-substituted benzotropine analogs that demonstrate high affinity binding ($K_i < 30$ nM) to the dopamine transporter and bind selectively (>100-fold) over the other monoamine transporters. These compounds block dopamine reuptake *in vitro* and yet do not demonstrate a cocaine-like behavioral profile in animal models of psychomotor stimulant abuse.

Structure-Activity Relationships suggest that these compounds interact at a binding domain that differs from that of cocaine at the dopamine transporter. The invention also describes cocaine analogs comprising N-substituted 2',3' and 3',3'' and 3',4''-analogs, which exhibit a cocaine-like behavioral profile. One of the compounds exhibits cocaine-like activity and anti-muscarinic receptor activity, which may improve its therapeutic utility. These compounds represent an unprecedented class of dopamine uptake inhibitors that may have potential as cocaine-abuse therapeutics, since they have

neurochemical similarities to cocaine and yet do not appear to have abuse liability. Further, radiolabeled analogs will be suitable for imaging the dopamine transporter in mammalian brain using SPECT and PET and thus would be useful in the diagnoses and monitoring of neurodegenerative disorders involving the dopaminergic system (e.g., Parkinson's disease). In addition, the invention provides pharmaceutical compositions comprising an analog of the invention and a pharmaceutically acceptable carrier excipient. (portfolios: Central Nervous System—Therapeutics, psychotherapeutics, drug dependence; Central Nervous System—Therapeutics, neurological, antiparkinsonian; Central Nervous System—Diagnostics, *in vivo*)

Conjugate Vaccine For Nontypeable Haemophilus Influenzae

X-X Gu (NIDCD), C-M Tsai (CBER), DJ Lim (NIDCD), JB Robbins (NICHD)
Serial No. 60/016,020 filed 23 Apr 96
Licensing Contact: Elaine Gese, 301/496-7056 ext. 282